1. Home
  2. ADPT vs AMN Comparison

ADPT vs AMN Comparison

Compare ADPT & AMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • AMN
  • Stock Information
  • Founded
  • ADPT 2009
  • AMN 1985
  • Country
  • ADPT United States
  • AMN United States
  • Employees
  • ADPT N/A
  • AMN N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • AMN Assisted Living Services
  • Sector
  • ADPT Health Care
  • AMN Health Care
  • Exchange
  • ADPT Nasdaq
  • AMN Nasdaq
  • Market Cap
  • ADPT 1.1B
  • AMN 1.0B
  • IPO Year
  • ADPT 2019
  • AMN 2001
  • Fundamental
  • Price
  • ADPT $7.33
  • AMN $18.49
  • Analyst Decision
  • ADPT Strong Buy
  • AMN Hold
  • Analyst Count
  • ADPT 5
  • AMN 8
  • Target Price
  • ADPT $9.40
  • AMN $38.50
  • AVG Volume (30 Days)
  • ADPT 2.4M
  • AMN 871.6K
  • Earning Date
  • ADPT 05-01-2025
  • AMN 05-08-2025
  • Dividend Yield
  • ADPT N/A
  • AMN N/A
  • EPS Growth
  • ADPT N/A
  • AMN N/A
  • EPS
  • ADPT N/A
  • AMN N/A
  • Revenue
  • ADPT $178,957,000.00
  • AMN $2,983,781,000.00
  • Revenue This Year
  • ADPT $21.20
  • AMN N/A
  • Revenue Next Year
  • ADPT $22.06
  • AMN $3.63
  • P/E Ratio
  • ADPT N/A
  • AMN N/A
  • Revenue Growth
  • ADPT 5.10
  • AMN N/A
  • 52 Week Low
  • ADPT $2.28
  • AMN $18.15
  • 52 Week High
  • ADPT $9.01
  • AMN $70.07
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 43.95
  • AMN 31.81
  • Support Level
  • ADPT $7.38
  • AMN $18.15
  • Resistance Level
  • ADPT $8.30
  • AMN $19.97
  • Average True Range (ATR)
  • ADPT 0.75
  • AMN 1.26
  • MACD
  • ADPT -0.04
  • AMN -0.26
  • Stochastic Oscillator
  • ADPT 33.85
  • AMN 8.92

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About AMN AMN Healthcare Services Inc

AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.

Share on Social Networks: